What did @emmabailafreiberg actually say?
She said it, pretty plainly: four months of KPV peptide use, five units roughly three times a week, and her eczema has "completely healed" — not just on her face, but bodywide. She also recommended that viewers with eczema speak to a specialist to "get KPV." That last part is worth noting. She stopped short of saying it's a cure, and she pointed people toward medical supervision. But "completely healed" is a strong phrase that deserves scrutiny.
One note on terminology: she opens by calling it "PPV" before correcting to KPV. This appears to be a slip, not a different compound. KPV is the peptide being discussed throughout, and that's what we'll fact-check.
Does the science back this up?
Partially, and with significant caveats. KPV (Lysine-Proline-Valine) is a tripeptide fragment derived from alpha-melanocyte-stimulating hormone (alpha-MSH). The anti-inflammatory research is real, but most of it is preclinical.
In a 2006 study by Bhatt et al. published in Peptides, KPV demonstrated anti-inflammatory effects in murine colitis models by inhibiting NF-kB signaling. A 2009 study by Dalmasso et al. in Journal of Proteome Research showed KPV could penetrate intestinal epithelial cells and reduce inflammatory cytokines. There's also research suggesting topical and oral KPV may modulate skin inflammation specifically — Singh and Bhatt (2012, Peptides) showed attenuation of contact hypersensitivity responses in mice.
The problem: there are no published randomized controlled trials in humans testing KPV for atopic dermatitis or eczema. The jump from mouse models to "completely healed" human eczema is not a small one. The mechanism is plausible. The clinical evidence for the specific claim? It isn't there yet.
What did they get wrong (or right)?
Credit where it's due: she told people to see a specialist rather than self-source the peptide. That's the right call. KPV sourced from unregulated research chemical suppliers has no quality guarantees, and dosing guidance from a TikTok video is not a substitute for a prescribing clinician.
What's more problematic is the phrasing "completely healed." Eczema is a chronic inflammatory condition with well-documented cycles of flare and remission. It is entirely possible, even common, for eczema to go into extended remission on its own or in response to lifestyle changes, seasonal shifts, or other concurrent interventions. Without a controlled setting, crediting one peptide for a full-body resolution is a reach. She also shared her dose — five units three times a week — which, regardless of her intent, functions as a dosing suggestion to viewers who may not have access to specialist care.
What should you actually know?
KPV is a legitimate subject of scientific inquiry. It is not approved by the FDA for any indication, and it is not a replacement for evidence-based eczema treatments such as topical corticosteroids, calcineurin inhibitors, or biologics like dupilumab, which has robust trial data behind it (Simpson et al., 2016, New England Journal of Medicine).
If you have eczema that is significantly affecting your quality of life, the evidence-based path starts with a dermatologist, not a peptide protocol. KPV may eventually prove useful in clinical settings — the mechanism is biologically interesting — but "may eventually" is doing a lot of work in that sentence. Right now, it is an experimental compound with no human trial data for atopic dermatitis. Treating a chronic skin condition with an unregulated peptide without medical supervision carries real risk, including unknown purity, contamination, and injection-site complications if administered subcutaneously.
- KPV's anti-inflammatory mechanism is supported by preclinical data, but human RCT evidence for eczema does not exist as of current literature.
- Eczema remission can occur spontaneously. Anecdotal resolution does not confirm causation.
- Sharing a specific dose on social media, even casually, reaches tens of thousands of people who may replicate it without clinical oversight.